Lewis C. Cantley
| Lewis C. Cantley | |
|---|---|
| Born |
February 20, 1949 West Virginia, United States |
| Residence | Boston, Massachusetts |
| Citizenship | United States |
| Nationality | American |
| Fields |
Biochemistry Cell Biology Systems Biology |
| Institutions |
Weill Cornell Medical College Harvard Medical School Beth Israel Deaconess Medical Center Tufts University Harvard University |
| Alma mater |
Wesleyan College Cornell University |
| Doctoral advisor | Gordon Hammes |
| Other academic advisors | Guido Guidotti |
| Known for |
PI-3-kinase Phosphatidylinositol (3,4,5)-trisphosphate Oriented Peptide Libraries/Scansite Phosphatidylinositol 5-phosphate |
Lewis C. Cantley (born February 20, 1949) is an American cell biologist and biochemist who has made significant advances to the understanding of cancer metabolism. Among his most notable contributions are the discovery and study of the enzyme PI-3-kinase, now known to be important to understanding cancer and diabetes mellitus. He is currently Meyer Director and Professor of Cancer Biology at the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine in New York City. He was formerly a professor in the Departments of Systems Biology and Medicine at Harvard Medical School, and the Director of Cancer Research at the Beth Israel Deaconess Medical Center, in Boston, Massachusetts. In 2016, he was elected Chairman of the Board for the Hope Funds for Cancer Research.
Cantley grew up in West Virginia, remaining in West Virginia at Wesleyan College where he graduated summa cum laude in chemistry in 1971. Cantley obtained his Ph.D. at Cornell University in Ithaca, New York, where he worked with Gordon Hammes on enzyme kinetics, using FRET to study enzyme conformational changes. In 1975 he moved to Harvard University for a postdoctoral fellowship under Guido Guidotti, where he discovered that an impurity in commercial preparations of ATP, vanadate, acts as a transition state analog for phosphate hydrolysis. In 1978 Cantley became assistant professor of Biochemistry and Molecular Biology at Harvard, being promoted to associate professor in 1981. In 1985, he became a full professor in physiology at Tufts University School of Medicine. In 1985 Cantley and colleagues Malcolm Whitman, David Kaplan, Tom Roberts, and Brian Schaffhausen made the seminal discovery of the existence of phosphoinositide-3-kinase (PI3K). In 1992, Cantley moved to Harvard Medical School as a Professor of Cell Biology and the Director of the Division of Signal Transduction at the former Beth Israel Hospital (now Beth Israel Deaconess Medical Center). In 2003, Cantley became a founding member of the newly formed Department of Systems Biology at Harvard Medical School. In 2007, Cantley also became the Director of Cancer Research at the Beth Israel Deaconess Medical Center. He joined the faculty of Weill Cornell Medicine and NewYork-Presbyterian Hospital in 2012. Dr. Cantley was elected the Chairman of the Board of the Hope Funds for Cancer Research in 2016.
...
Wikipedia